Stanford Doctor to Get $191 Million for Cancer-Fighting Biotech.

(Bloomberg) -- A Stanford University professor and stem cell pioneer whose first job in science paid $25 a month is poised to receive a $191 million windfall from the sale of the immunotherapy biotech firm he co-founded. Irv Weissman, 80, owns 4.2% of Forty Seven Inc., which Gilead Sciences Inc. agreed to buy for about $4.9 billion, a remarkable amount considering the company's market value was less than $250 million just five months ago. Working in their Stanford lab, Weissman, fellow founder Ravindra Majeti and Siddhartha Jaiswal identified the role of CD47 proteins in the progression of cancer stem cells into a more malignant form. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)